Results 261 to 270 of about 10,488 (304)

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

The role of GALAD score in the surveillance of hepatocellular carcinoma. [PDF]

Sci Rep
İstemihan Z, Şenkal İV, Karaca D, Nuriyev K, Rustamzade A, Genç Uluçeçen S, Dağcı G, Yağlı MA, Gurbanov A, Telli P, Çavuş B, Çifcibaşı Örmeci A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S.   +15 more
europepmc   +1 more source

Molecular pathology of testicular germ cell tumours: an update for practicing pathologists

Histopathology, Volume 88, Issue 1, Page 214-229, January 2026.
Molecular testing for isochromosome 12p is usually only necessary in difficult cases that encompass metastases or recurrent diseases including somatic‐type malignancies. So far, no breaking progress has been made in the field of targeted therapy as TGCTs only rarely show targetable molecular alterations.
Alexander Fichtner, Stefanie Zschäbitz, Daniel Nettersheim, Felix Bremmer   +3 more
wiley   +1 more source

Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma. [PDF]

Clin Exp Med
Núñez K, Sandow T, Burton J, Hibino M, Gimenez J, Cohen A, Mehta N, Thevenot P.   +7 more
europepmc   +1 more source

Wertigkeit der regionalen Therapie des hepatozellulären Karzinoms [PDF]

, 2007
Dogan, Selin
core  

Second edition ICCR dataset for testicular germ cell tumours: a reporting guide for histopathological diagnosis of orchiectomy specimens

Histopathology, Volume 88, Issue 1, Page 252-264, January 2026.
The current 2nd edition Orchiectomy dataset offers a rigorously validated, internationally developed checklist that supports high‐quality, standardised reporting and promotes clinical confidence across diverse healthcare settings. All ICCR datasets are freely available to the global pathology community via the ICCR website ([www.iccr‐cancer.org](http://
Felix Bremmer, Fleur Webster, Gedske Daugaard, Robert J. Hamilton, Muhammad T. Idrees, Chia‐Sui Kao, Kosuke Miyai, Maria Rosaria Raspollini, John R. Srigley, Satish Tickoo, Asli Yilmaz, Thomas Wagner, Daniel M. Berney   +12 more
wiley   +1 more source

Alpha-fetoprotein and carbohydrate antigen 19-9 as prognostic biomarkers in acute liver failure: A retrospective study. [PDF]

J Int Med Res
Qi R, Wang X, Kuang Z, Shang X, Lin F, Chang D, Mu J.   +6 more
europepmc   +1 more source

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Gastroenterology and Hepatology, Volume 41, Issue 1, Page 302-311, January 2026.
ABSTRACT Background and Aim Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC). Methods Of 835 patients with uHCC treated
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Ryu Sasaki, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Tomotake Shirono, Yuki Kanayama, Hisamitsu Miyaaki, Sohji Nishina, Tetsuji Takayama, Hideki Kobara, Motoyuki Otsuka, Taro Takami, Takumi Kawaguchi, Hiroki Kawashima, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +24 more
wiley   +1 more source

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B

Liver International, Volume 46, Issue 1, January 2026.
ABSTRACT Background & Aims Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP‐B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP‐B.
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Satoshi Miuma, Tomotake Shirono, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Yuki Kanayama, Atsushi Naganuma, Sohji Nishina, Tetsuji Takayama, Hideki Kobara, Motoyuki Otsuka, Hiroki Kawashima, Taro Takami, Takumi Kawaguchi, Hisamitsu Miyaaki, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +25 more
wiley   +1 more source

Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma. [PDF]

Biomark Med
Yang Y, Jin A, Zhou Y, Wu W, Zhang C, Pan B, Wang B, Sun Y, Guo W.   +8 more
europepmc   +1 more source